[go: up one dir, main page]

MA32621B1 - Traitement de maladie auto-immune et inflammatoire - Google Patents

Traitement de maladie auto-immune et inflammatoire

Info

Publication number
MA32621B1
MA32621B1 MA33682A MA33682A MA32621B1 MA 32621 B1 MA32621 B1 MA 32621B1 MA 33682 A MA33682 A MA 33682A MA 33682 A MA33682 A MA 33682A MA 32621 B1 MA32621 B1 MA 32621B1
Authority
MA
Morocco
Prior art keywords
autoimmune
treatment
inflammatory disease
biological activity
multiple sclerosis
Prior art date
Application number
MA33682A
Other languages
Arabic (ar)
English (en)
Inventor
Stewart Leung
Lixin Li
Xuebin Liu
Hongtao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA32621B1 publication Critical patent/MA32621B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux procédés de traitement de la sclérose en plaques et d'autres maladies auto-immunes ou troubles inflammatoires, et des antagonistes, comprenant des protéines de liaison isolées pour une utilisation dans les nouveaux procédés. La présente invention concerne en outre un procédé de traitement de la sclérose en plaques comprenant la neutralisation de l'activité biologique de il-7 par liaison à cd127 ou il-7. Les protéines de liaison isolées peuvent également neutraliser l'activité biologique de tslp.
MA33682A 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire MA32621B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19
PCT/US2009/053136 WO2010017468A1 (fr) 2008-08-08 2009-08-07 Traitement de maladie auto-immune et inflammatoire

Publications (1)

Publication Number Publication Date
MA32621B1 true MA32621B1 (fr) 2011-09-01

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33682A MA32621B1 (fr) 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire

Country Status (23)

Country Link
US (2) US20110287000A1 (fr)
EP (1) EP2318442A1 (fr)
JP (1) JP2011530533A (fr)
KR (1) KR20110044777A (fr)
CN (1) CN102177179A (fr)
AR (1) AR072985A1 (fr)
AU (1) AU2009279471A1 (fr)
BR (1) BRPI0916945A2 (fr)
CA (1) CA2733432A1 (fr)
CL (1) CL2011000269A1 (fr)
CO (1) CO6341640A2 (fr)
CR (1) CR20110118A (fr)
DO (1) DOP2011000041A (fr)
EA (1) EA201100150A1 (fr)
IL (1) IL211034A0 (fr)
MA (1) MA32621B1 (fr)
MX (1) MX2011001477A (fr)
NZ (1) NZ590994A (fr)
PE (1) PE20110382A1 (fr)
TW (1) TW201018482A (fr)
UY (1) UY32038A (fr)
WO (1) WO2010017468A1 (fr)
ZA (1) ZA201100974B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
MA34004B1 (fr) 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
JPWO2011152503A1 (ja) * 2010-06-02 2013-08-01 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
US20130295111A1 (en) * 2010-08-10 2013-11-07 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
CN113144178B (zh) * 2014-04-29 2024-10-18 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2016044189A1 (fr) * 2014-09-15 2016-03-24 Genentech, Inc. Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
AR103891A1 (es) * 2015-03-11 2017-06-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
CA2997809A1 (fr) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps specifiques d'il-7r-alpha pour le traitement la leucemie lymphoblastique aigue
RS59223B1 (sr) 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera
MX2019006577A (es) * 2016-12-09 2019-10-07 Ose Immunotherapeutics Anticuerpos y polipeptidos dirigidos contra cd127.
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
KR20230128134A (ko) * 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
CN117343173A (zh) * 2019-03-07 2024-01-05 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
MX2022005083A (es) 2019-10-28 2022-07-19 Medimmune Ltd Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (fr) 2020-02-13 2022-12-21 Amgen Inc. Traitement de la dermatite atopique avec un anticorps anti-tslp
AU2021219839A1 (en) 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
JP2023551935A (ja) 2020-12-02 2023-12-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ－７結合タンパク質および医学的療法におけるそれらの使用
AR129445A1 (es) 2022-05-27 2024-08-28 Glaxosmithkline Ip Dev Ltd USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
EP4455308A1 (fr) 2023-04-24 2024-10-30 Les Laboratoires Servier Signatures géniques il-7r
AU2024284143A1 (en) * 2023-06-07 2025-10-23 Fbd Biologics Limited Engineered il-7 variants and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994028160A1 (fr) * 1993-06-01 1994-12-08 Toray Industries, Inc. Anticorps monoclonal, procede de production, et utilisation
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
WO2005123774A2 (fr) * 2004-06-15 2005-12-29 Erol Fikrig Anticorps de polypeptides du virus du nil occidental
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
GT200600065A (es) * 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CA2513350A1 (fr) * 2005-03-02 2006-09-02 Sydney West Area Health Service Traitement contre la sclerose en plaques
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
AR072985A1 (es) 2010-10-06
PE20110382A1 (es) 2011-06-27
US20100040616A1 (en) 2010-02-18
UY32038A (es) 2010-03-26
CN102177179A (zh) 2011-09-07
MX2011001477A (es) 2011-03-25
DOP2011000041A (es) 2011-02-28
EA201100150A1 (ru) 2011-10-31
WO2010017468A1 (fr) 2010-02-11
BRPI0916945A2 (pt) 2015-11-24
CA2733432A1 (fr) 2010-02-11
KR20110044777A (ko) 2011-04-29
NZ590994A (en) 2012-09-28
CL2011000269A1 (es) 2012-07-20
CR20110118A (es) 2011-07-28
AU2009279471A1 (en) 2010-02-11
CO6341640A2 (es) 2011-11-21
ZA201100974B (en) 2012-10-31
IL211034A0 (en) 2011-04-28
EP2318442A1 (fr) 2011-05-11
US20110287000A1 (en) 2011-11-24
JP2011530533A (ja) 2011-12-22
TW201018482A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
Sarkar et al. Molecular signatures of neuroinflammation induced by αsynuclein aggregates in microglial cells
Xu et al. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
MA33717B1 (fr) Immunoconjugués ciblés
MX338421B (es) Anticuerpos fosfoespecificos que reconocen la proteina tau.
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MX2011010353A (es) Composicion farmaceutica.
MA29836B1 (fr) Proteines de fusion avec l'albumine
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
PH12011502389B1 (en) Monoclonal antibody
DE60224879D1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
MX2010001111A (es) Mutantes mcp-1 que antagonizan glicosaminoglicano y metodos para utilizar los mismos.
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l'osteoformation et l'autorenouvellement des cellules
EP2438962A3 (fr) Polynucléotides et séquences de polypeptides impliqués dans le procédé de remodelage des os
RU2013137466A (ru) Бис-met-гистоны
BRPI0506890A (pt) derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo
MA28969B1 (fr) Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes
MY149448A (en) Interleukin-21 receptor binding proteins
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
Kloske et al. Advancements in immunity and dementia research: Highlights from the 2023 AAIC Advancements: Immunity Conference
EP2275547A3 (fr) Polynucléotides et séquences de polypeptide impliquées dans le procédé de remodelage des os